On February 1, 2024 General Proximity reported the company has been awarded a NIH NCI SBIR Phase I grant (Press release, General Proximity, FEB 1, 2024, View Source [SID1234649814]). This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This award represents a pivotal step forward in our mission to innovate and develop transformative treatments for patients facing critical unmet needs.